Skip to content

Clinical outcomes of Descemet Stripping Only in treatment for Fuchs Endothelial Corneal Dystrophy in Thai participants

Clinical outcomes of Descemet Stripping Only in treatment for Fuchs Endothelial Corneal Dystrophy in Thai participants

Status
Unknown
Phases
Phase 1Phase 2
Study type
Interventional
Source
TCTR
Registry ID
TCTR20221019001
Enrollment
5
Registered
2022-10-19
Start date
2022-11-01
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

18 years and older thai participants who have Fuchs Endothelial corneal Dystrophy with clinical presentation of Photophobia or night blindness with Snellen Best Corrected Visual Acuity lower than 20/40 with modified Krachmer grading of corneal dystrophy not more than gr.IV Fuchs Endothelial Corneal Dystrophy , Fuchs Endothelial Dystrophy , FECD ,FED ,Descemet Stripping Only , DSO

Interventions

DSO is performed by remove the small central corneal Descemets membrane only. and post operative use of 0.4% Ripasudil qid wait to see if the surrounding endothelial cells migrate from the periphery t
Experimental Procedure/Surgery
Descemets Stripping Only (DSO)

Sponsors

None listed

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: 1.18 years and older thai participants 2.Patient who have Fuchs Endothelial corneal Dystrophy with clinical presentation of 2.1 Photophobia or visual problems in dim light . 2.2 Snellen Best Corrected Visual Acuity lower than 20/40 2.3 Modified Krachmer grading of corneal dystrophy not more than gr.IV with peripheral corneal endothelial cells greater than 1,000 cells/mm2 and corneal thickness 580-640 um

Exclusion criteria

Exclusion criteria: 1.No light perception 2.Have chronic disease that effect on wound healing process , or uncontrolled underlying disease eg. uncontrolled Hypertension and Chronic kidney disease. 3.Immunocopromise patient. 4.Not well co-operative patient or patient who's inconvenient to follow-up 5.Patient who have other eye pathology that effects on vision eg. infectious/autoimmune keratitis or significant cataract 6.History of Rho Kinase Inhibitors drug allergy

Design outcomes

Primary

MeasureTime frame
visual outcome at 12 months after intervention visual acuity, Endothelial cell count, Corneal Thickness

Secondary

MeasureTime frame
complication of DSO surgery 12 months after intervention visual acuity, Endothelial cell count, Corneal Thickness

Countries

Thailand

Contacts

Public ContactVilavun Puangsricharern

Faculty of Medicine, Chulalongkorn University

vilavun@hotmail.com0830122999

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026